Table 1 SABOR case control demographic and clinical variables
From: A case control study of sarcosine as an early prostate cancer detection biomarker
Control | Prostate cancer | ||
|---|---|---|---|
Median (range) | Median (range) | ||
or N (%) | or N (%) | P value | |
n = 251 | n = 246 | ||
Age | 64.8 (45.0–83.5) | 64.1 (46.0–88.5) | 0.80 |
Race | 0.02 | ||
White | 171 (68.1) | 139 (56.5) | |
African American | 34 (13.5) | 38 (15.4) | |
Other | 46 (18.3) | 69 (28.0) | |
At least one previous prostate biopsy | 43 (17.1) | 53 (21.5) | 0.26 |
Abnormal Digital Rectal Exam | 7 (2.8) | 70 (28.5) | <0.001 |
Family history of prostate cancer | 28 (11.2) | 62 (25.2) | <0.001 |
Prostate-specific antigen (ng/mL) | 1.0 (0.1–8.4) | 3.4 (0.0–93.8) | <0.001 |
Sarcosine uM in 20 uL serum (all samples) | 16.2 (6.4–53.6) | 15.8 (6.2–42.5) | 0.40 |
Sarcosine (only PSA 2–10 ng/mL) | 16.3 (8.1–37.6) | 15.8 (6.2–42.5) | 0.34 |
Gleason grade | N/A | ||
5 | 7 (2.8) | ||
6 | 158 (64.2) | ||
7 | 56 (22.8) | ||
8 | 12 (4.9) | ||
9 | 8 (3.3) | ||
Missing | 5 (2.0) |